Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: April 24, 2024
Liver
fibrosis,
as
a
consequence
of
chronic
liver
disease,
involves
the
activation
hepatic
stellate
cell
(HSC)
caused
by
various
injuries.
Emerging
evidence
suggests
that
HSC
during
an
inflammatory
state
can
lead
to
abnormal
accumulation
extracellular
matrix
(ECM).
Investigating
novel
strategies
inhibit
and
proliferation
holds
significant
importance
for
treatment
fibrosis.
As
member
doublecortin
domain-containing
family,
domain
containing
2
(DCDC2)
mutations
neonatal
sclerosing
cholangitis,
but
its
involvement
in
fibrosis
remains
unclear.
Therefore,
this
study
aims
elucidate
role
DCDC2
Our
findings
revealed
reduction
expression
both
human
fibrotic
tissues
carbon
tetrachloride
(CCl
International Journal of Molecular Medicine,
Journal Year:
2024,
Volume and Issue:
54(1)
Published: May 20, 2024
Lactate
is
a
byproduct
of
glycolysis,
and
before
the
Warburg
effect
was
revealed
(in
which
glucose
can
be
fermented
in
presence
oxygen
to
produce
lactate)
it
considered
metabolic
waste
product.
At
present,
lactate
not
only
recognized
as
substrate
that
provides
energy,
but
also
signaling
molecule
regulates
cellular
functions
under
pathophysiological
conditions.
Lactylation,
post‑translational
modification,
involved
development
various
diseases,
including
inflammation
tumors.
Liver
disease
major
health
challenge
worldwide.
In
normal
liver,
there
net
uptake
caused
by
gluconeogenesis,
exhibiting
higher
clearance
rate
compared
with
any
other
organ.
Therefore,
abnormalities
metabolism
lead
liver
disease,
metabolism‑related
genes
used
for
predicting
prognosis
disease.
Targeting
production,
regulating
transport
modulating
lactylation
may
potential
treatment
approaches
However,
currently
systematic
review
summarizes
role
diseases.
present
review,
diseases
fibrosis,
non‑alcoholic
fatty
acute
failure
hepatocellular
carcinoma
summarized
aim
provide
insights
future
research.
Drug Delivery and Translational Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 24, 2025
Abstract
Liver
fibrosis
is
still
a
serious
health
concern
worldwide,
and
there
increasing
interest
in
mesenchymal
stem
cells
(MSCs)
with
tremendous
potential
for
treating
this
disease
because
of
their
regenerative
paracrine
effects.
Recently,
many
researches
have
focused
on
using
the
released
exosomes
(EXOs)
from
to
treat
liver
rather
than
parent
themselves.
MSC-derived
EXOs
(MSC-EXOs)
demonstrated
favourable
outcomes
similar
cell
treatment
terms
regenerative,
immunomodulatory,
anti-apoptotic,
anti-oxidant,
anti-necroptotic,
anti-inflammatory
anti-fibrotic
actions
several
models
fibrosis.
are
superior
terms,
including
lower
immunogenicity
risk
tumour
formation.
However,
maintaining
stability
efficacy
after
vivo
transplantation
remains
major
challenge
clinical
applicability.
Therefore,
strategies
been
applied
engineering,
such
as
parental
modification
or
modifying
directly
achieve
optimum
performance
Herein,
we
discuss
underlying
mechanisms
an
overview
available
therapies,
among
them
EXOs.
We
also
summarise
recent
developments
improving
effectiveness
advantages
limitations
these
approaches
upcoming
applications.
Graphical
Cells,
Journal Year:
2022,
Volume and Issue:
11(9), P. 1500 - 1500
Published: April 29, 2022
Cirrhosis
is
a
severe
form
of
liver
fibrosis
that
results
in
the
irreversible
replacement
tissue
with
scar
liver.
Environmental
toxicity,
infections,
metabolic
causes,
or
other
genetic
factors
including
autoimmune
hepatitis
can
lead
to
chronic
injury
and
result
inflammation
fibrosis.
This
activates
myofibroblasts
secrete
ECM
proteins,
resulting
formation
fibrous
scars
on
Fibrosis
regression
possible
through
removal
pathophysiological
causes
as
well
elimination
activated
myofibroblasts,
reabsorption
tissue.
To
date,
wide
range
antifibrotic
therapies
has
been
tried
tested,
varying
degrees
success.
These
include
use
growth
factors,
cytokines,
miRNAs,
monoclonal
antibodies,
stem-cell-based
approaches,
approaches
target
ECM.
The
positive
preclinical
clinical
studies
raise
prospect
viable
alternative
transplantation
near
future.
present
review
provides
synopsis
recent
treatment
modalities
for
cirrhosis,
brief
summary
trials
have
conducted
date.
BMC Chemistry,
Journal Year:
2023,
Volume and Issue:
17(1)
Published: June 16, 2023
Abstract
Background
The
carbazole
skeleton
is
an
important
structural
motif
occurring
naturally
or
synthesized
chemically
and
has
antihistaminic,
antioxidant,
antitumor,
antimicrobial,
anti-inflammatory
activities.
Objectives
This
study
aimed
to
design
synthesize
a
novel
series
of
derivatives
evaluate
their
antiproliferative
antioxidant
Methods
compounds
were
characterized
utilizing
HRMS,
1
H-,
13
C
APT
-NMR,
assessed
for
anticancer,
antifibrotic,
effects
reference
biomedical
procedures.
In
addition,
the
AutoDock
Vina
application
was
used
perform
in-silico
docking
computations.
Results
A
in
current
study.
Compounds
10
11
found
have
stronger
effect
than
2
–
5
against
HepG2,
HeLa,
MCF7
cancer
cell
lines
with
IC
50
values
7.68,
10.09,
6.44
µM,
respectively.
Moreover,
compound
9
showed
potent
activity
HeLa
value
7.59
µM.
However,
except
,
all
moderate
activities
CaCo-2
range
43.7–187.23
All
these
compared
positive
control
anticancer
drug
5-Fluorouracil
(5-FU).
most
anti-fibrotic
compound,
cellular
viability
LX-2
57.96%
at
µM
concentration
comparison
5-FU.
4
1.05
±
0.77
5.15
1.01
Conclusion
Most
promising
antiproliferative,
antifibrotic
biological
effects,
further
in-vivo
investigations
are
needed
approve
disapprove
results.
Asian Journal of Pharmaceutical Sciences,
Journal Year:
2023,
Volume and Issue:
18(2), P. 100779 - 100779
Published: Jan. 29, 2023
Complications
of
the
liver
are
amongst
world's
worst
diseases.
Liver
fibrosis
is
first
stage
problems,
while
cirrhosis
last
stage,
which
can
lead
to
death.
The
creation
effective
anti-fibrotic
drug
delivery
methods
appears
critical
due
liver's
metabolic
capacity
for
drugs
and
presence
insurmountable
physiological
impediments
in
way
targeting.
Recent
breakthroughs
agents
have
substantially
assisted
fibrosis;
nevertheless,
working
mechanism
medications
not
fully
understood,
there
a
need
design
systems
that
well-understood
aid
cirrhosis.
Nanotechnology-based
regarded
be
but
they
been
adequately
researched
delivery.
As
result,
capability
nanoparticles
hepatic
was
explored.
Another
approach
targeted
delivery,
considerably
improve
efficacy
if
designed
target
stellate
cells
(HSCs).
We
addressed
numerous
strategies
HSCs,
eventually
fibrosis.
Recently
genetics
proved
useful,
delivering
genetic
material
place
also
investigated
where
different
techniques
depicted.
To
summarize,
this
review
paper
sheds
light
on
most
recent
gene-based
nano
lately
shown
useful
treatment
